NCT06065735View on ClinicalTrials.gov

Concentration-QT Study of Paroxetine in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions

Anxiety Disorders

Interventions

DRUG

Paroxetine

Paroxetine will be administered

Trial Locations (1)

HA1 3UJ

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT06065735 - Concentration-QT Study of Paroxetine in Healthy Adults | Biotech Hunter | Biotech Hunter